Insider buying last 90 days
No open-market insider purchases were filed for CBLL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CBLL insider filing, plotted on the chart in Gekko.Open CBLL in Gekko
NASDAQ: CBLL
CeriBell (CBLL) Stock Analysis & Forecast
Oct 12 close
$25.26+1.63 (+6.9%)
Gekko Brief
Oct 12 closeCeriBell closed at $25.26 on 12 October 2026, +6.9% on the day. The price sits above both the 50-day ($23.40) and 200-day ($20.45) moving averages, inside a 52-week range of $10.85 to $25.63. The GekkoIndex reads 53.6, in the Neutral zone, down 1.7 points over five sessions. Gekko Fair Value is $25.31, so the price is 0.2% below it.
The next earnings report is due on 3 November 2026, 22 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 8.1% across the report.
6 firms rate the stock: 6 buy, 0 hold and 0 sell, with a consensus target of $28.57. A typical daily move is about 4%, and a typical 20-day move about 9.7%. On the swing-trade checklist, 1 item reads supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
CeriBell price vs fair value
Close $25.26200-day averageGekko Fair Value $25.31
CeriBell quick facts
- Market cap
- $958.4M
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.70
- Revenue, TTM
- $102.0M
- Profit margin
- -64.7%
- Dividend yield
- —
- Beta
- —
- Volume
- 696,838 avg 366,382
- 1-year return
- +97.0%
- Typical daily move
- ±4%
- Typical 20-day move
- ±9.7%
- 50-day average
- $23.40
- 200-day average
- $20.45
- Next earnings
- Nov 3 after close
- Shares outstanding
- 38.38M
CeriBell swing-trade checklist
CeriBell scores 1 supportive, 2 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $25.26 is above the 50-day ($23.40) and 200-day ($20.45) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.6, Neutral
Reading 53.6 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
0.2% below
Price is within 5% of Gekko Fair Value (0.2% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
CeriBell stock chart and price history
CeriBell closed at $25.26 on Oct 12, 2026, +97.0% over the past year, inside a 52-week range of $10.85 to $25.63.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.9%
- 3 months
- +32.0%
- 6 months
- +32.0%
- 1 year
- +97.0%
The full CBLL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CBLL in Gekko
Follow CeriBell through every session
Put CBLL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CBLL in GekkoFree for 7 days. No credit card required.
About CeriBell
CeriBell develops artificial intelligence-based EEG technology used to detect and manage neurological conditions right at a patient's bedside, rather than requiring transport to a specialized lab. Its central product, the Ceribell System, brings EEG monitoring into urgent care settings where fast answers about brain activity are needed. Alongside this platform, the company makes single-use EEG headbands and small, battery-operated recording units that work with the system.
The headbands and portable recorders appear to function as companion equipment to the core system, supporting its use in acute, time-sensitive care situations. Together these offerings form a bedside diagnostic approach aimed at settings where immediate neurological assessment matters.
CeriBell traces its roots to 2014, when it was founded as Brain Stethoscope, Inc., before adopting its current name in August 2015. The company is headquartered in Sunnyvale, California. Its shares trade on the NASDAQ under the ticker CBLL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- ceribell.com
CeriBell GekkoIndex: the smart money zone
CeriBell’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.6, in the Neutral zone, down 1.7 points over five sessions.
53.6Neutral
Down 1.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 29 | +2.3% | +4.5% | ||
| Accumulation | 186 | −0.3% | +0.4% | ||
| Neutral (current zone) | 244 | −0.1% | −0.1% | ||
| Distribution | 31 | +5.1% | +10.8% | ||
| Selling | 5 | Too few readings yet | |||
Average CBLL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CBLL price, zone by zone.Track CBLL in Gekko
Is CeriBell stock overvalued? Gekko Fair Value
CeriBell trades 0.2% below Gekko Fair Value of $25.31, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what CeriBell shares are worth, recalculated every trading day.
$25.31
Gekko Fair Value, Oct 9, 2026
0.2% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open CBLL in Gekko
CeriBell insider and Congress trading
No open-market insider purchases were filed for CeriBell, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CBLL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CBLL, plotted on the chart in Gekko.Open CBLL in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold CBLL.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
CeriBell earnings: next date and track record
CeriBell reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- −$0.50
- Revenue estimate
- $29.17M
5 of 8reports beat the EPS estimate
±8.1%average move across the report
2 of 7reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- Ceribell reported a strong Q2 2026 with revenue of $28.1M, up 33% year-over-year and 6% sequentially, driven by same-store growth and account additions (32 accounts, 712 active). Record gross margin of 92% was reported, including $1.6M in tariff refunds; excluding the refund gross margin was 89%. Management emphasized sustained commercial execution, multiple FDA algorithm clearances, a limited-market delirium pilot with positive early results, a neonate indication rollout, and a next-generation hardware platform planned for limited release and broader launch in 2027. Management reiterated a strategy of reinvesting high gross profits into sales infrastructure, R&D, and targeted commercialization (strategic account management and regional system team). OpEx was elevated due to stock-based compensation and IP litigation. Management expects gross margins to remain in the high-80s for 2026 and is focused on achieving cash-flow breakeven, but did not provide explicit revenue or 2027 guidance.
- Guidance
- Expect to maintain gross margins in the high-80s percentage range for the remainder of 2026. Management did not provide explicit revenue or full-year 2027 guidance; they reiterated adjusted EBITDA loss has been roughly around $10M historically and did not provide a specific timeline for cash-flow breakeven.
- Risks flagged
- Elevated IP litigation costs; seasonality (Q2 low ICU census); historical tariff exposure (though refunds were received); stock-based compensation volatility increasing OpEx in Q2; long sales cycles and dependencies on rep productivity/maturation; company not yet cash-flow breakeven; potential need to expand sales resources if delirium gains momentum.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.51 est −$0.45 | $28.10M est $27.28M | +13.3% |
| May 11, 2026 | −$0.38 est −$0.39 | $26.49M est $26.09M | −17.1% |
| Feb 24, 2026 | −$0.36 est −$0.41 | $24.78M est $23.93M | −5.2% |
| Nov 4, 2025 | −$0.37 est −$0.43 | $22.59M est $23.95M | +3.9% |
| Aug 5, 2025 | −$0.38 est −$0.40 | $21.20M est $21.76M | −16.1% |
| May 8, 2025 | −$0.36 est −$0.43 | $20.49M est $20.54M | −0.2% |
| Feb 25, 2025 | −$0.40 est −$0.31 | $18.53M est $19.30M | −0.9% |
| Aug 28, 2024 | −$0.37 est $0.00 | $14.86M est $17.55M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
CeriBell stock forecast and analyst price targets
Analysts’ average 12-month price target for CeriBell is $28.57, +13.1% from the last close, from 6 firms rating the stock in the last 90 days.
$28.57consensus 12-month target, +13.1% from the last close
Now $25.26Avg $28.57
Low $26High $33
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 2 | TD Cowen | $33 | +30.6% |
| Sep 30 | William Blair | — | — |
| Sep 21 | BTIG | $30 | +18.8% |
| Sep 4 | William Blair | — | — |
| Sep 3 | Raymond James | $29 | +14.8% |
−0.1%average 20-day move after past Neutral readings
±4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CeriBell market cap and key statistics
CeriBell’s market cap is $958.4M and revenue of $102.0M over the last twelve months.
Valuation
- Market cap
- $958.4M
- EPS, TTM
- −$1.70
- Gekko Fair Value
- $25.31
Trading
- Volume
- 696,838
- Avg volume, 20 days
- 366,382
- 52-week high
- $25.63
- 52-week low
- $10.85
- Shares outstanding
- 38.38M
Financials
- Revenue, TTM
- $102.0M
- Profit margin
- -64.7%
- Return on equity
- -43.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±4%
- Typical 20-day move
- ±9.7%
CeriBell peers
CeriBell’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
CeriBell stock FAQ
What is CeriBell’s market cap?
CeriBell’s market cap is $958.4M at the Oct 12, 2026 close of $25.26, with 38.38M shares outstanding.
What is the CeriBell stock forecast?
The consensus analyst 12-month price target for CeriBell is $28.57, +13.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is CeriBell stock overvalued or undervalued?
On Gekko’s estimate CeriBell is about fair value: the Oct 12, 2026 close of $25.26 is 0.2% below Gekko Fair Value of $25.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does CeriBell report earnings next?
CeriBell is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of −$0.50 per share on revenue of $29.17M. CeriBell beat the earnings estimate in 5 of its last 8 reports, moving 8.1% on average across the report.
What is CeriBell’s 52-week high and low?
CeriBell’s 52-week high is $25.63 and its 52-week low is $10.85; it closed at $25.26 on Oct 12, 2026, +97.0% over the past year. Over the last five years the shares peaked at $32.75 on Dec 12, 2024.
Is CeriBell stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 4 items with data read as supportive (trend), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See CeriBell the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.